menu
    • menu
    [{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Aarhus University Hospital | Bispebjerg Hospital | Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigshospitalet \/ Aarhus University Hospital | Bispebjerg Hospital | Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Rigshospitalet \/ Aarhus University Hospital | Bispebjerg Hospital | Johnson & Johnson"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Nephrology","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Johnson & Johnson"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"Phase IV","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Groningen \/ Johnson & Johnson"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ Johnson & Johnson"},{"orgOrder":0,"company":"Retinset","sponsor":"Instituto Universitario de Oftalmobiolog\u00eda Aplicada","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SPAIN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Endocrinology","graph2":"Phase I","graph3":"Retinset","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Retinset \/ Instituto Universitario de Oftalmobiolog\u00eda Aplicada","highestDevelopmentStatusID":"6","companyTruncated":"Retinset \/ Instituto Universitario de Oftalmobiolog\u00eda Aplicada"},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Swedish Heart Lung Foundation | The Swedish Research Council | Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Endocrinology","graph2":"Phase II","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Institutet \/ Swedish Heart Lung Foundation | The Swedish Research Council | Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Institutet \/ Swedish Heart Lung Foundation | The Swedish Research Council | Johnson & Johnson"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Edinburgh \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"University of Edinburgh \/ Pfizer Inc"},{"orgOrder":0,"company":"Geropharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"RUSSIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Undisclosed","graph2":"Phase I","graph3":"Geropharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Geropharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Geropharm \/ Undisclosed"},{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet for Suspension","sponsorNew":"Lupin Ltd \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Natco Pharma"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Christoph Hehrlein","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Christoph Hehrlein","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Christoph Hehrlein"}]

    Find Clinical Drug Pipeline Developments & Deals for Bosentan

    Menu

    Bosentan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lupin Ltd

                            India arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Natco Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lupin & Natco Pharma Gets Final Approval for its ANDA for Bosentan Tablets

                            Details : Tracleer-Generic (bosentan) is an endothelin receptor antagonist small molecule drug candidate, which is indicated for the treatment of pulmonary arterial hypertension.

                            Product Name : Tracleer-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 10, 2025

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Natco Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Humanis

                            Turkey arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Humanis

                            Turkey arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets

                            Details : Tracleer (Bosentan) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.

                            Product Name : Tracleer

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zydus Lifesciences

                            India arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus Receives Tentative Approval from The USFDA for Bosentan Tablets for Oral Suspension

                            Details : Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. It is developed for for the treatment of PAH in pediatric patients aged 3 years and older with idiopathic or congenial PAH to improve pulmonary vascular resistanc...

                            Product Name : Bosentan-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 15, 2023

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Geropharm

                            Russia arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Geropharm

                            Russia arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Bosentan 125 mg Tablets Immediate Release (IR) Versus Tracleer® 125 mg Tablets IR I...

                            Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2019

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Retinset

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Retinset

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Instituto Universitario de Oftalmobiología Aplicada

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety of Bosentan in Type II Diabetic Patients

                            Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2019

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Instituto Universitario de Oftalmobiología Aplicada

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University Medical Center Groningen

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University Medical Center Groningen

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis

                            Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Scleroderma, Systemic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 24, 2015

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Radboud University Medical Center

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Radboud University Medical Center

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ET-blockade and Exercise-induced Vascular Adaptations in T2DM

                            Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2013

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Johnson & Johnson

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Johnson & Johnson

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bosentan in Systemic Sclerosis

                            Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Scleroderma, Systemic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 18, 2011

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Johnson & Johnson

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Johnson & Johnson

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persistent Pulmonary Hypertension of the Newborn

                            Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Persistent Fetal Circulation Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 08, 2011

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Johnson & Johnson

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Johnson & Johnson

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Christoph Hehrlein

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers o...

                            Details : Tracleer is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Raynaud Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 22, 2011

                            Lead Product(s) : Bosentan Hydrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Christoph Hehrlein

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth